High Q Technologies Deploys Quantum EPR Sensors to Accelerate Drug Discovery for Alzheimer's and Neurodegenerative Diseases
核心洞察
High Q Technologies (搜索), founded at the University of Waterloo in 2013, is developing a quantum sensor called Fathom that uses electron paramagnetic resonance (EPR) spectroscopy to map protein motion with extreme precision.
The Fathom platform aims to accelerate drug discovery for neurodegenerative diseases such as Alzheimer's by years and could significantly reduce resources required in drug testing stages.
EPR spectroscopy detects all protein configurations simultaneously, overcoming limitations of traditional techniques that struggle to resolve the full range of protein motion.
An Ontario-based startup is bringing quantum sensing technology to pharmaceutical R&D, aiming to shave years off the drug discovery timeline for neurodegenerative diseases. High Q Technologies (搜索), founded in 2013 by biomedical researchers and drug developers at the University of Waterloo, has developed a quantum-enabled electron paramagnetic resonance (EPR) spectrometer called Fathom that maps moving protein structures with extreme precision.
The company's core innovation addresses a fundamental challenge in structural biology: proteins are not static entities. "Proteins, like most biological structures, are flexible," said Don Carkner, managing director at High Q. "When proteins interact with other molecules, they flex, twist and reconfigure as part of their function. In general, drugs work by affecting such motion."
Traditional structural biology techniques, Carkner explained, tend to be sensitive only to a protein's most common configuration and can struggle to resolve the full range of motion. "EPR is able to detect all configurations at once," he noted, positioning the technology as a complementary and potentially superior approach to understanding dynamic protein behavior.
Quantum-Enabled Protein Dynamics
The Fathom platform leverages quantum sensors to perform EPR spectroscopy, a technique that measures the magnetic properties of unpaired electrons in proteins. By capturing the complete conformational landscape of a protein in motion, the technology provides drug developers with a more comprehensive view of how potential therapeutic candidates might interact with their targets.
"Drug discovery is increasingly focused on understanding how proteins behave in motion," said Carkner. "With Fathom, quantum-enabled EPR spectroscopy provides a way to study these dynamic systems."
According to High Q, the device could slash the resources typically required in the stages of drug testing. Beyond its primary application in studying protein dynamics, EPR can also serve as a screening tool to ensure that samples are ideally prepared before being measured by traditional equipment, potentially lowering development costs while positively impacting the pipeline.
Global Expansion Through Creative Biostructure (搜索) Partnership
High Q recently announced a partnership with Shirley, N.Y.-based Creative Biostructure (搜索), a contract research organization, to expand access to its quantum technology for pharmaceutical research on a global scale. Creative Biostructure brings a substantial existing client base, with over 3,000 customers in 60 countries and regions, including numerous large pharmaceutical companies and high-profile academic institutions.
Under the collaboration, Creative Biostructure (搜索) will provide scientific consultation, experimental design support, and workflow guidance for organizations implementing High Q's Fathom EPR spectroscopy platform. The partnership represents a significant step toward making quantum-enabled drug discovery tools accessible to the broader pharmaceutical research community.
Institutional Backing
High Q's mission to advance domestic biotechnology capabilities is supported by the government of Canada, Waterloo-based venture capital firm Quantum Valley Investments (搜索), and the University of Waterloo's Transformative Quantum Technologies accelerator. This combination of public and private backing underscores the strategic importance of quantum technologies in the future of drug discovery, particularly for challenging indications such as Alzheimer's disease (搜索) where traditional approaches have faced significant hurdles.